Arai, T., Takahashi, K., Nakahara, S. and Kubo, A. (1980). The structure of a novel antitumor antibiotic, saframycin A. Cellular and Molecular Life Sciences 36: 1025- 1027.
Atmaca, H., Bozkurt, E., Uzunoglu, S. and Karaca, B. (2013). A diverse induction os apoptosis by trabectedin in MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2+/ER-) breast cancer cells. Toxicology Letters, 221(2): 128-136.
Aune, G.T., Futura, T. and Pommier, Y. (2002). Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action. Anticancer Drugs, 13: 545-555.
Bergmann, W. and Stempien, M.F. (1957). Contributions to the study of marine products. XLIII. The nucleosides of sponges. V. The synthesis of spongosine. The
journal of Organic Chemistry, 22: 1575-1577.
Beumer, J.H., Schellens, J.H.M and Beijnen, J.H. (2005). Hepatotoxicity and metabolism of trabectedin: a literature review. Pharmacological Research, 51: 391-398.
Carballo, J.L. (2000). Distribución de Ecteinascidia turbinata (Ascidiacea: Perophoridae) en los manglares de la Península de Yucatán, Mexico. Revista de
Biología Tropical, 48(2-3): 365-369.
Carballo, J.L., Naranjo, S., Kukurtzü, B., de La Calle, F. and Hernández-Zanuy, A. (2000). Production of Ecteinascidia turbinata (Ascidiacea: Perophoridae) for obtaining anticancer compounds. Journal of the World Aquaculture Society, 31(4): 481-490.
Chen, J., Chen, M., Bois-Choussy, M. and Zhu, J. (2006) Total Synthesis of Ecteinascidin 743. Journal of the American Chemical Society 128: 87-89.
Corey, E.J. and Gin, D.Y. (1996). A Convergent Enantioselective Synthesis of the Tetrahydroisoquinoline Unit in the Spiro ring of Ecteinascidin 743. Tetrahedron Letters 37: 7163-7166.
Corey, E.J., Gin, D.Y. and Kania, R.S. (1996). Enantioselective Total Synthesis of Ecteinascidin 743. Journal of the American Chemical Society 118: 9202-9203.
Cuevas, C., Pérez, M., Martín, M.J., Chicharro, J.L., Fernández-Rivas, C., Flores, M., Francesch, A., Gallego, P., Zarzuelo, M., de la Calle, F., Garcia, J., Polanco, C., Rodríguez, I. and Manzanares, I. (2000). Synthesis of Ecteinascidin ET-743 and Phthalascidin Pt-650 from Cyanosafracin B. Organic Letters 2: 2545-2548.
Cuevas, C. and Francesch, A. (2009). Development of Yondelis® (trabectedin, ET- 743). A semisythesis process solves the supply problem. Natural Products Reports, 26: 322-337.
Damia, G., Silvestri, S., Carrasca, L., Filiberti, L., Faircloth, G.T., Liberti, G., Foiani, M. and D’Incalci, M. (2001). Unique pattern of ET-743 activity in different celular systems with defined deficiences in DNA-repair pathways. International Journal of
Cancer, 92: 583-588.
De la Calle, F. (2007). Fármacos de origen marino. Treballs de la SCB, 58: 141-155.
D’Incalci, M. (2013). Trabectedin mechanism of action: what´s new?. Future Oncology, 9: 5-10.
D’ Incalci, M., Erba, E. Damia, G., Galliera,E., Carrasca, L., Marchini, S., Mantovani, R., Tognon, G., Fruscio, R., Jimeno, J. and Faircloth, G.T. (2002). Unique features of the mode of action of ET-743. The oncologist, 7: 210-216.
D’Incalci, M. and Jimeno, J. (2003). Preclinical and clinical results with the nature marine product ET-743. Expert Opinion on Investigational Drugs, 12: 1843-1853.
Duckworth, A.R., Samples, G.A., Wright, A.E. and Pomponi, S.A. (2004). In vitro culture of the ascidian Ecteinascidia turbinata to supply the antitumor compounds ecteinascidins. Aquaculture, 241(1-4): 427-439.
EMEA (2007). Scientific Discussion (https://www.nice.org.uk/guidance/ta185/ documents/emea-scientific-discussion2).
Endo, A., Yanagisawa, A., Abe, M., Tohma, S., Kan, T. and Fukuyama, T. (2002). Total Synthesis of Ecteinascidin 743. Journal of the American Chemical Society, 124: 6552-6554.
Erba, E., Bergamaschi, D., Bassano, L., Damia, G., Ronzoni, S., Faircloth, G.T. and D’Incalci, M. (2001). Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism os action. European Journal Cancer, 37, 97-105.
Fajarningsih, N.D. (2012). An emerging marine biotechnology: Marine drug discovery.
Squalen, 7(2): 88-98.
Fayette, J., Coquard, I.R., Albert, L., Ranchère, D., Boyle, H. and Blay, J.Y. (2005). ET-743: A novel agent with activity in soft tissue sarcomas. Oncologist, 10(10): 827- 832.
FDA (2015). U.S Food and Drug Administration. Trabectedin. (23 Octubre 2015 http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm468914.htm)
(Consultada el 12 de Enero de 2016).
Fishlock, D. and Williams R.M. (2008). Synthetic Studies on Et-743. Assembly of the Pentacyclic Core and a Formal Total Synthesis. Journal of Organic Chemistry 73: 9594-9600.
García-Cagide, A., Hernández-Zanuy, A. and Cárdenas, A. (2005). Fecundity and early larval development of the ascidian Ecteinascidia turbinata (Ascidiacea: Perophoridae) in Cuba. Boletín de Investigaciones Marinas y Costeras – INVEMAR, 34(1): 141-159.
Gerwick, W.H. and Moore, B.S. (2012). Lessons from the past and charting the future of marine natural products drug discovery and chemical biology. Chemistry and
Biology, 19(1): 85-98.
Gordaliza, M. (2015). Handbook of anticancer drugs from Marine Origin,- Chapter 35: Cytotoxic terpene-purines and terpene-quinones from the sea. Springer. 805 pp.
Harati, K., Chromik, A.M., Bulut, D., Goertz, O., Hahn, S., Hirsch, T., Klein-Hitpass, L., Lehnhardt, M., Uhl, W. and Daigeler, A. (2012). TRAIL and taurolidine enhance the anticancer activity of doxorubicin, trabectedin and mofosfamide in HT1080 human fibrosarcoma cells. Anticancer Research, 32(7): 2967-2984.
Hérnandez-Zanuy, A., García-Cagide, A, Borrero, N. and Carballo, JL. (2007). Alimentación de la ascidia Ecteinascidia turbinata (Ascidiaca: Perophoridae) en dos áreas de manglar de Cuba. Revista de Biología Tropical, 55(2): 499-507.
Herrero, A.B., Martin-Castellanos, C., Marco, E., Gago, F. and Moreno, S. (2006). Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Research, 66: 8155-8162.
Hurley, L.H. and Zewail-Foote, M. (2001). The antitumor agent ecteinascidin 743: characterization of its covalent DNA adducts and chemical stability. Adv Exp Med Biol, 500: 289-299.
Ikeda, Y., Shimada, Y., Honjo, K., Okumoto, T. and Munakata, T. (1983). Safracins, new antitumor antibiotics. Journal of Antibiotics 36: 1290-1294.
Ikeda, Y., Idemoto, H., Hirayama, F., Yamamoto, K., Iwao, K., Asao, T. and Munakata, T. (1983). Safracins, New Antitumor Antibiotics. Journal of Antibiotics 36: 1279-1283.
Irschik, H., Trowitzschi-Kienast, W., Gerth, K., Hofle, G. and Reichenbach, H. (1988). Saframycin Mx1, a new natural saframycin isolated from a myxobacterium. Journal of
Antibiotics 41: 993-998.
Jeedigunta, S., Krenisky, J.M. and Kerr, R.G. (2000). Diketopiperazines as advanced intermediates in the biosynthesis of Ecteinascidins. Tetrahedron, 56: 3303-3307.
Kerr, R.G. and Miranda, N.T. (1995). Biosynthetic Studies of Ecteinascidins in the Marine Tunicate Ecteinascidia turbinata. Journal of Natural Products 58: 1618-1621.
Kim, S. and Kalimuthu, S. (2015). Handbook of anticancer drugs from Marine Origin,- Chapter 1: Introduction to anticancer drugs from marine origin.Springer. 805 pp.
Koketsu, K., Watanabe, K., Suda, H., Oguri, H. and Oikawa, H. (2010). Reconstruction of the saframycin core scaffold defines dual Pictet-Spengler mechanisms. Nature
Chemical Biology 6: 408-411.
Kong, D.X., Jiang, Y.Y. and Zhang, H.Y. (2010). Marine natural products as sources of novel scaffolds: achievement and concern. Drug Discovery Today, 15: 884-886.
Laborda, A.J. y San Sebastian, M.M. (2015). Drogas marinas: la fauna marina como fuente de compuestos antitumorales. AmbioCiencias, 13: 34-51.
Le cesne, A., Youine, A., Blay, J., Delaloge, S., Make, R.G., Misset, J., Frontelo, P., Nieto, A. and Jiao, J.J. (2012). A retrospective pooled analysis of trabectedin safety in 1132 patients with solid tumors treated in phase II clinical trials. Investigational New
Drugs, 30: 1193-1202.
Li, W.W., Takahashi, N., Jhanwar, S., Cordon-Cardo, C., Elisseyeff, Y., Jimeno, J., Faircloth, G. and Bertinon, J.R. (2001). Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as potent cytotoxic agent.
Clinical Cancer Research, 7(9): 2908-2911.
Liu, Y. (2012). Renaissance of Marine Natural Product Drug Discovery and Development. Marine Sci Res Development, 2: 106.
Lyerla, T.A., Lyerla, J.H. and Fisher, M. (1975). Pigmentation in the orange tunicate,
Ecteinascidia turbinata. The biological bulletin, 149(1): 178-185.
Martinez, E.J. and Corey E.J. (2000). A New, More Efficient, and Effective Process for the Synthesis of a Key Pentacyclic Intermediate for Production of Ecteinascidin and Phthalascidin Antitumor Agents. Organic Letters 2: 993-996.
Martinez-Serra, J., Maffiotte, E., Martin, J., Bex, T., Navarro-Palou, M., Ros, T., Plazas, J.M., Vögler, O., Gutiérrez, A., Amat, J.C., Ramos, R., Sauz, C., Ginés, J., Alemany, R., Diaz, M. and Besalduch, J. (2011). Yondelis® (ET-743, trabectedin) sensitizes cancer cell lines to CD95-mediated call death: new molecular insight into the mechanism of action. European Journal of Pharmacology, 658(2-3): 57-64.
Martins, A., Vieira, H., Gaspar, H. and Santos, S. (2014). Marketed Marine Natural Products in the Pharmaceutical and Cosmeceutical Industries: Tips for Sucess. Marine
Drugs, 12: 1066-1101.
Mayer, A.M.S., Glaser, K.B., Cuevas, C., Jacobs, R.S., Kem, W., Little, R.D., Mclntosh, J.M., Newman, D.J., Potts, B.C. and Shuster, D.E. (2010). The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends in Pharmacological
Miguélez, F. (2010). Los otros usos del mar. Netbiblo, La Coruña, 153 pp.
Molinski, T.M., Dalisay, D.S., Lievens, S.L. and Saludes, J.P. (2009). Drug development from marine natural products. Natural Reviews Drug Discovery, 8: 69-85.
Montaser, R. and Luesch, H. (2011). Marine natural products: a new wave of drugs?.
Future Med. Chem, 3(12): 1475-1489.
Munro, M.H.G., Blunt, J.W., Dumdei, E.J., Hickford, S.J.H., Lill, R.E., Shangxiao, L., Battershill, C.N. and Duckworth, A.R. (1999). The discovery and development of marine compounds with pharmaceutical potential. J Biotechnol, 70: 15-25.
Pharmamar1 (2016). Informe a 31 de Marzo de 2016 (https://www.pharmamar.com/wp- content/uploads/2016/04/INFORME-MARZO-2016.pdf).
Pharmamar2 (2016). Informe a 19 de Mayo de 2016 (https://www.pharmamar.com/wp- content/uploads/2016/05/HECHO-RELEVANTE-PHARMA-MAR-19.05.2016.pdf).
Petersen, J.K. (2006). Ascidian suspension feeding. Journal of Experimental Marine
Biology and Ecology, 342: 127-137.
Rath, C.M., Janto, B., Earl, J., Ahmed, A., Hu, F.Z., Hiller, L., Dahlgren, M., Kreft, R., Yu, F., Wolff, J.J., Kweon, H.K., Christiansen, M.A., Håkansson, K., Williams, R.M., Ehrlich, G.D. and Sherman, D.H. (2011). Meta-omic characterization of the marine invertebrate microbial consortium that produces the chemotherapeutic catural product ET-743. ACS Chemical Biology 6: 1244-1256.
Rinehart, K.L., Holt, T.G., Fregeau, N.L., Stroh, J.G., Keifer, P.A., Sun, F., Li, L.H. and Martin, D.G. (1990). Ecteinascidins 729,743, 745, 759A, 759B, and 770: Potent Antitumor Agents from the Caribbean Tunicate Ecteinascidia turbinate. Journal of
Organic Chemistry 55: 4512-4515.
Sakai, R., Jares-Erijman, E.A., Manzanares, I., Silva Elipe, M.V. and Rinehart, K.L. (1996). Ecteinascidins: putative biosynthetic precursors and absolute stereochemistry.
Sakai, R., Rinehart, K.L., Guang, Y. and Wang, A.H.J. (1992). Additional antitumor ecteinascidins from a Caribbean tunicate: Crystal structures and activities in vivo.
Proceedings of the Natural Academic of Sciences 89: 11456-11460.
Sanamyan, K., Monniot, C. (2007). Ecteinascidia turbinata Herdman, 1880. (http://www.marinespecies.org/aphia.php?p=taxdetails&id=103756) (Consultada el 16 de Abril de 2016).
Sawadogo, W.R., Boly, R., Cerella, C., Teiten, M.H., Dicato, M. and Diederich, M. (2015). A Survey of Marine Natural Compounds and Their Derivates with Anti-cancer Activity Reported in 2012. Molecules, 20(4): 7097-7142.
Scotlandi, K., Perdichizzi, S., Manara, M.C., Serra, M., Benini, S., Cerisano, V., Strammiello, R., Mercuri, M., Reverter-Branchat, G., Faircloth, G., D’Incalci, M. and Picci, P. (2002). Effectiveness of ecteinascidin-743 against Drug-sensitive and – resistant bone tumor cells. Clinical Cancer Research, 8(12), 3893-3903.
Scott, J.D. and Williams, R.M. (2002). Chemistry and Biology of Tetrahydroisoquinoline Antitumor Antibiotics. Chemical Reviews 102: 1669-1730.
Sigel, M.M., Wellham, L.L., Lichter, W., Dudeck, L.E., Gargus, J.L. and Lucas, L.H. (1969). Food-Drugs From the Sea: Proceedings, 1969. Marine Technology Society. 281 pp.
Sigel, M.M., McCumber, L.J., Hightower, J.A., Hayasaka, S.S., Huggins, E.M. Jr. and Davis, J.F. (1983). Ecteinascidia turbinata Extract Activates Components of Inflammatory Responses Throughout the Phylogenetic Spectrum. American Zoologist 23: 221-227.
Simmons, T.L., Andrianasolo, E., McPhail, K., Flatt, P. and Gerwick, W.H. (2005). Marine natural products as anticancer drugs. Mol Cancer Ther, .4(2): 333-342.
Soares, D.G., Escargueil, A.E., Poindessous, V., Sarasin, A., de Gramont, A., Bonatto, D., Herique, J.A. and Larsen, A.K. (2007). Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin-743. Proc Natl Acad Sci, 104: 13062-13067.
Sugasawa, K. (2008). Xerodema pigmentation genes: functions inside and outside DNA repair. Carcinogenesis, 29, 455-465.
Sweat, L.H. (2009). Smithsonian Marine Station at Fort Pierce. (7 mayo 2009; http://www.sms.si.edu/irlspec/Ectein_turbin.htm) (Consultada el 21 de Abril de 2016).
Takebayashi, Y., Pourquier, P., Zimonjic, D.B., Nakayama, K., Emmert, S., Veda, T., Urasaki, Y., Kanzaki, A., Akiyama, S., Popsau, N., Kraemer, K.H. and Pommier, Y. (2001). Antiproliferative activity of ecteinascidin 743 is depend upon transcription- coupled nucleotide-excision repair. Nature Medicine, 7: 961-966.
Tavecchio, M., Simone, M., Erba, E., Chiolo, I., Liberti, G., Foiani, M., D’Incalci, M. and Damia, G. (2008). Role of homologous recombination in trabectedin-induced DNA damage. European Journal Cancer, 44: 609-618.
Vazquez, E. and Young, C.M. (1996). Responses of compound ascidian larvae to haloclines. Marine Ecology Progress Series, 133: 179-190.
Voss, G.L. (1980). Seashore life of Florida and the Caribbean. Dover Publications. Mineola, New York, USA. 199 pp.
Wright, A.E., Forleo, D.A., Gunawardana, G.P., Gunasekera, S.P., Koehn, F.E. and McConnell, O.J. (1990). Antitumor Tetrahydroisoquinoline Alkaloids from the Colonial Ascidian Ecteinascidia turbinata. The Journal of Organic Chemistry 55: 4508-4512.
Young, C.M. and Bingham, B.L. (1987). Chemical defense and aposemantic coloration in larvae of the ascidian Ecteinascia turbinata. Marine Biology, 96(4): 539-544.
Zheng, J., Chan, X., Furuuchi, T., Wright, B.J.D., Zhou, B., Guo, J. and Danishefsky, S.J. (2006). Stereospecific Formal Total Synthesis of Ecteinascidin 743. Angewandte